INIFY Laboratories AB
OSE:INIFY
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.26
7.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
I
|
INIFY Laboratories AB
OSE:INIFY
|
282.5m NOK |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
90.2B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
63B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
72.3B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27.6B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
21.8B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.3B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20.4B USD |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
14.3B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR |
Loading...
|
|
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
11.1B AUD |
Loading...
|
Market Distribution
| Min | -5 565 412.8% |
| 30th Percentile | -5.3% |
| Median | 3% |
| 70th Percentile | 7.5% |
| Max | 12 228% |
Other Profitability Ratios
INIFY Laboratories AB
Glance View
INIFY Laboratories AB engages in the provision of cancer diagnostics through laboratory services within pathology. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2022-06-20. The firm uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The firm origins from ContextVision.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for INIFY Laboratories AB is -8 682.1%, which is above its 3-year median of -20 209.8%.
Over the last 5 months, INIFY Laboratories AB’s Net Margin has increased from -30 660.6% to -8 682.1%. During this period, it reached a low of -30 660.6% on May 30, 2023 and a high of -9 759% on Oct 30, 2023.